Law & Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law & Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE)
May 16th, 2009
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) announced the presentation of new data from multiple analyses of its Phase III pivotal clinical trial evaluating the efficacy, safety and tolerability of rifaximin - a non-absorbed (<0.4%), gut selective antibiotic - in adult patients with hepatic encephalopathy (HE). These data will be presented during one oral and two poster sessions at the annual meeting of the European Association for the Study of the Liver (EASL) being held this week in Copenhagen (April 22 – 26, 2009). These new data, from a large, randomized, placebo-controlled study of 299 patients, showed that patients who received rifaximin (1100...
Source: Law & Health Weekly (2009-05-16)
|
